** Hong Kong-listed shares of Chinese oncology treatments developer Beigene Ltd 6160.HK jump 10.1% to HK$117.40
** Stock marks biggest intraday pct rise since December 2022
** Stock hits the highest point since Dec 10, and on course to snap two sessions of decline, if gains hold; stock is fourth-biggest pct gainer in Hang Seng Composite Index .HSCI, which adds 0.9%
** Beigene says it expects to achieve "positive" operating income for full-year 2025 pursuant to U.S. generally accepted accounting principles
** Beigene's Shanghai stock 688235.SS surges 6.7% to 174.18 yuan, its highest since Dec 10
** Hang Seng Commerce & Industry Index .HSNC rises 1.1%, healthcare index .HSCIH surges 2.4% and Hang Seng Index .HSI gains 0.9%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.